Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a lab notebook. Cyclerion Therapeutics packs pages of sGC pharmacology data, trial protocols, and milestone royalty terms into every document, making it hard to spot cash-runway risks or FDA-related 8-K updates.
Stock Titan removes that barrier. Our AI engine parses each Cyclerion filing the moment it hits EDGAR, then delivers plain-English highlights—whether you’re skimming the Cyclerion Therapeutics quarterly earnings report 10-Q filing for R&D spend, or need Cyclerion insider trading Form 4 transactions in real time. Investors can instantly compare segments, track Cyclerion executive stock transactions Form 4, or dive into a Cyclerion annual report 10-K simplified summary without wading through clinical jargon.
Every document type is covered: 8-K material events explained when trial data drop, proxy statement executive compensation details for governance checks, and Form S-3 shelves that fund future studies. Use cases include:
- Flagging Cyclerion Form 4 insider transactions real-time before catalysts
- Monitoring trial-cost trends via our Cyclerion earnings report filing analysis
- Understanding Cyclerion SEC documents with AI to gauge licensing revenue potential
Cyclerion Therapeutics, Inc. (CYCN) reported that Chief Financial Officer Rhonda M. Chicko was granted an option to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The grant, reported with a transaction date of 08/07/2025, is under the 2019 Equity Incentive Plan. Of the 25,000 shares, 8,750 are immediately exercisable and 16,250 vest in monthly installments beginning August 31, 2025 and ending February 28, 2028, subject to continued service. The option expires August 6, 2035, and the reporting person is shown as the direct beneficial owner of the 25,000 option shares following the transaction.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
